SingleSkin & Cosmetic

Palmitoyl Tripeptide-5 200mg

Topical synthetic lipopeptide studied for collagen stimulation via thrombospondin-1 mimicry, utilized in cosmetic formulation research.

Mechanism

Designed to mimic thrombospondin-1 binding to release latent TGF-beta, activating fibroblast collagen synthesis while lipid moieties suppress matrix metalloproteinases.

Dosing

Incorporated into topical formulations targeting 10 to 300 ppm (approximately 1 to 30 mg of pure peptide per 100 g batch), applied once or twice daily.

Reconstitution

Typically solubilized into aqueous or glycerin vehicle phases at 10 to 300 ppm active concentration, requiring no bacteriostatic water for injection.

Storage

Keep raw lyophilized peptide powder tightly sealed, protected from light, and refrigerated at 2-8°C in a dry environment.

Mix & measure Palmitoyl Tripeptide-5 200mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Palmitoyl Tripeptide-5 200mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Low End Research Target	10 ppm (1 mg per 100 g base) daily	Topical base application (N/A)
In-Vivo Study Benchmark	25–250 ppm (2.5–25 mg per 100 g base) 1-2x daily	Topical base application (N/A)
Upper Documented Range	300 ppm (30 mg per 100 g base) 1-2x daily	Topical base application (N/A)

Reconstitution Steps

1
Verify lyophilized raw material purity, molecular identity (611.9 g/mol), and batch certificate of analysis prior to use.
2
Calculate the targeted concentration (10 to 300 ppm active peptide) based on the mass of the final cosmetic base batch.
3
Prepare a measurable stock solution (such as 200 mg per 20 mL aqueous/solvent mixture) to ensure micro-milligram precision.
4
Incorporate the measured aliquot into the aqueous phase of the cosmetic vehicle at temperatures below 40°C.
5
Homogenize gently, ensuring the final formulation pH remains between 3.0 and 7.0, and store protected from light.

Supplies Needed

Peptide Vial

Lyophilized Palmitoyl Tripeptide-5 powder (200 mg) container for precise laboratory formulation.

Insulin Syringes (U-100)

Not utilized; this peptide is designated strictly for topical formulations and must not be injected.

Bacteriostatic Water

Not recommended; topical laboratory preparation relies on cosmetic solvents, water-based serums, or glycerin vehicles.

Alcohol Swabs

Employed to sanitize laboratory work surfaces, spatulas, and formulation measuring vessels.

Why researchers study it

Collagen synthesis stimulation through latent TGF-beta activation pathways

Inhibition of extracellular matrix metalloproteinases (MMP-1 and MMP-3)

Dermal remodeling, skin elasticity, and facial fine line reduction

Investigation of carrier and nano-encapsulation delivery systems for transdermal passage

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Palmitoyl Tripeptide-5 (commonly associated with the trademark SYN-COLL) is a synthetic lipopeptide composed of a palmitic acid chain conjugated to the sequence Lys-Val-Lys. Originally designed to replicate the biological mechanism of thrombospondin-1, it is investigated for its potential to trigger the activation of latent tissue growth factor-beta (TGF-beta), thereby stimulating extracellular matrix production in dermal fibroblasts. In research formulations, it is examined for cosmetic endpoints including elasticity, dermal thickening, and wrinkle reduction. Unlike injectable research peptides, Palmitoyl Tripeptide-5 is distributed as a topical research material and must not be reconstituted for parenteral administration. Commercial cosmetic references typically cite a 1% to 3% concentration based on an aqueous glycerin master-mix containing roughly 0.1% to 1% pure peptide, yielding an effective concentration of only 10 to 300 parts per million in final emulsions. Mistaking pure lyophilized powder percentages with pre-diluted trade solutions represents a primary point of error in laboratory formulations. Independent evaluations emphasize that despite extensive inclusion across cosmeceutical preparations, peer-reviewed evidence investigating the isolated peptide remains sparse. Most published investigations utilize multi-active cocktails or complex nanocarriers. Furthermore, experimental diffusion models have observed limited passive transdermal permeation for the standalone lipopeptide, suggesting vehicle composition and mechanical delivery systems heavily influence active dermal availability.

References

1.PubChem CID 11950477, NCBI, 2026 — Chemical structure, formula, and molecular identity of Palmitoyl Tripeptide-5
2.DSM Nutritional Products / Pentapharm, Technical Dossier, 2013 — SYN-COLL formulation guidelines and composition specifications
3.Cauchard et al., Biochemical Pharmacology, 2004 — Activation of latent TGF-beta 1 and inhibition of MMPs by thrombospondin-like tripeptides
4.Ribeiro et al., Journal of Biological Chemistry, 1999 — Activation sequence of thrombospondin-1 interacting with latency-associated peptide
5.Shariati Pour et al., Molecules, 2023 — Delivery of active peptides by supramolecular hydrogels and transdermal permeation assessment
6.Resende et al., Pharmaceuticals, 2021 — Analysis and clinical evidence evaluation of synthetic peptides in cosmetic products
7.Avcil et al., Journal of Cosmetic Dermatology, 2019 — Clinical efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches
8.Chen et al., Colloids and Surfaces B: Biointerfaces, 2024 — Supramolecular collagen nanoparticles for transdermal peptide delivery